Results 51 to 60 of about 147,672 (267)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib

IJU Case Reports, 2023
Introduction The effectiveness of nivolumab plus cabozantinib for metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus remains unclear.
Michikata Hayashida, Yuji Miura, Takeshi Yamaguchi, Makoto Tanaka, Taro Yamanaka, Kohji Takemura, Suguru Oka, Kazushige Sakaguchi, Shinji Ito, Shinji Urakami   +9 more
doaj   +1 more source

A Case of Sarcomatoid Renal Cell Carcinoma With Osseous Metaplasia and Papillary Renal Cell Carcinoma Metastasis

Clinical Pathology, 2019
Sarcomatoid renal cell carcinoma is an uncommon and aggressive renal tumor with rapid disease progression. A median survival time is only 4-9 months after diagnosis. Osteogenic differentiation is a rare feature of the tumor.
Hui Zhang, Nasma K Majeed, Roohollah Sharifi, Grace Guzman   +3 more
doaj   +1 more source

PRCC (papillary renal cell carcinoma) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on PRCC (papillary renal cell carcinoma), with data on DNA, on the protein encoded, and where the gene is implicated.
F Desangles, Jean-Loup Huret
openaire   +2 more sources

Clear Cell Papillary Renal Cell Carcinoma: A Potential Mimic of Conventional Clear Cell Renal Carcinoma on Core Biopsy

Case Reports in Urology, 2015
Clear cell papillary renal cell carcinoma (CCP-RCC) is a recently described, relatively uncommon variant of renal cell carcinoma (RCC) with a reported incidence of 4.1%. Thought to only arise in those with end stage renal disease, CCP-RCC is increasingly
Heath Liddell, Anton Mare, Sean Heywood, Genevieve Bennett, Hin Fan Chan   +4 more
doaj   +1 more source

Expression of nectin-4 in papillary renal cell carcinoma

Discover Oncology, 2022
Abstract Background Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and checkpoint inhibitors are currently treatments of choice.
Zschäbitz, Stefanie, Mikuteit, Marie, Stöhr, Christine, Herrmann, Edwin, Polifka, Iris, Agaimy, Abbas, Trojan, Lutz, Ströbel, Philipp, Becker, Frank, Wülfing, Christian, Barth, Peter, Stöckle, Michael, Staehler, Michael, Stief, Christian, Haferkamp, Axel, Hohenfellner, Markus, Duensing, Stefan, Macher-Göppinger, Stephan, Wullich, Bernd, Noldus, Joachim, Brenner, Walburgis, Roos, Frederik C., Walter, Bernhard, Otto, Wolfgang, Burger, Maximilian, Schrader, Andres Jan, Hartmann, Arndt, Erlmeier, Franziska, Steffens, Sandra   +28 more
openaire   +5 more sources

Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma.

Annals of Translational Medicine, 2019
Background The papillary renal cell carcinoma (pRCC) is a rare subtype of renal cell carcinoma with limited investigation. Our study aimed to explore a robust signature to predict the prognosis of pRCC from the perspective of mutation profiles ...
Chuanjie Zhang, Yuxiao Zheng, Xiao Li, Xin Hu, Feng Qi, Jun Luo   +5 more
semanticscholar   +1 more source

Mitophagy-associated genes PINK1 and PARK2 are independent prognostic markers of survival in papillary renal cell carcinoma and associated with aggressive tumor behavior

Scientific Reports, 2020
The aim of this study was to investigate the mitophagy-related genes PINK1 and PARK2 in papillary renal cell carcinoma and their association with prognosis. In silico data of PINK1 and PARK2 were analyzed in TCGA cohorts of papillary renal cell carcinoma
A. Simon, Y. Tolkach, L. Esser, J. Ellinger, C. Stöhr, M. Ritter, S. Wach, H. Taubert, C. Stephan, A. Hartmann, G. Kristiansen, V. Branchi, M. Toma   +12 more
semanticscholar   +1 more source

MET as a Target in Papillary Renal Cell Carcinoma [PDF]

Clinical Cancer Research, 2014
Abstract The biology underlying papillary renal cell carcinoma (pRCC) is largely unknown, and no specific therapies have been developed for advanced disease. The elucidation of the MET pathway status in types I and II pRCC may help to select patients who are more likely to benefit from MET inhibitors.
André P. Fay, Toni K. Choueiri, Toni K. Choueiri, Sabina Signoretti   +3 more
openaire   +3 more sources

Needle tract seeding in renal tumor biopsies: experience from a single institution

Diagnostic Pathology, 2021
Background Percutaneous needle biopsy of renal masses has been increasingly utilized to aid the diagnosis and guide management. It is generally considered as a safe procedure.
Yan Zhou, Paari Murugan, Faqian Li, Lihong Bu   +3 more
doaj   +1 more source

DAB2IP Plays Important Clinical Significance and Correlates With Immune Infiltration in Renal Cell Carcinoma

Technology in Cancer Research & Treatment, 2020
Background: Disabled homolog 2-interacting protein is a new member of the Ras GTPase superfamily involved in the regulation of cell proliferation, apoptosis, and metastasis.
Haoyuan Cao MM, Jiandong Zhang MD, Wei Wang MD   +2 more
doaj   +1 more source